New AI tool shows promise in treating depression, anxiety, and eating disorders
According to the team behind the project, even a dramatic increase in the number of human therapists would not be sufficient to meet the growing demand for mental health care. Their solution: a digital platform that can provide reliable, science-based support to individuals dealing with conditions such as anxiety, depression, and eating disorders.
A recently published clinical study highlighted Therabot's effectiveness in reducing symptoms across those disorders. A follow-up trial is planned to compare the chatbot's performance directly against traditional therapy methods.
The medical and psychological communities appear cautiously optimistic about the use of AI in this space. One healthcare innovation leader from a major psychological association described the potential of AI-driven mental health support as 'promising,' provided it is developed ethically and responsibly. However, concerns remain, especially regarding how younger users may interact with such tools.
The development team behind Therabot has invested nearly six years into building the chatbot, emphasizing user safety and therapeutic value over commercial gain. Rather than relying solely on real-world therapy transcripts, the developers constructed detailed simulated conversations to train the AI, enhancing its understanding of patient-caregiver dynamics.
The team is also considering launching a nonprofit branch to help ensure access for individuals who cannot afford traditional therapy.
In contrast to many commercially driven apps, which critics say often prioritize engagement over well-being, the Therabot developers aim to build genuine therapeutic connections and trust with users. Experts warn that many apps in the market feed users what they want to hear, which may mislead or emotionally manipulate, especially younger audiences.
While the U.S. Food and Drug Administration does not formally certify AI-based mental health apps, it may authorize them for marketing after reviewing pre-market submissions. The agency has acknowledged the potential for digital tools to improve access to behavioral therapy.
Other developers in the space are also working on AI-powered therapy solutions. One competing app claims to be able to detect signs of crisis or suicidal ideation and send alerts to prevent harm. The creators of this app argue that their design avoids the risks associated with less rigorously developed chatbots.
Despite their potential, experts agree that AI therapy tools are currently better suited for day-to-day emotional support rather than severe psychiatric crises. However, their constant availability makes them a valuable resource for individuals seeking support at unconventional hours—something not always possible with human therapists.
Some individuals have already turned to general AI platforms for mental health support, with one user reporting significant personal benefit in managing trauma-related stress. While such tools are not officially designed for therapy, their accessibility and responsiveness offer comfort to those in distress.
As AI continues to shape the future of mental health care, developers and medical professionals alike stress the importance of balancing innovation with ethical responsibility and robust oversight.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arab Times
a day ago
- Arab Times
FDA announces large-scale recall of popular deodorants
NEW YORK, July 20: The U.S. Food and Drug Administration (FDA) has announced a major recall involving tens of thousands of Power Stick deodorants produced by A.P. Deauville due to manufacturing defects. According to the agency, more than 67,000 cases of roll-on deodorants are affected by the recall, which was prompted by deviations from Current Good Manufacturing Practices (CGMP) — a set of industry standards that ensure quality and safety in pharmaceutical and personal care product manufacturing. The recalled items include: Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh, 1.8 oz (53 mL)n Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz (53 mL)n Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz (53 mL)n The deodorants were distributed across the United States. Consumers are encouraged to check the FDA's website for specific lot numbers tied to the affected products. While no press release has been issued by A.P. Deauville at this time, the recall is ongoing, and the FDA continues to monitor the situation. 'Recalls are important because they protect the public from products that may cause injury, illness, or even death,' the FDA stated in its notice. The agency emphasizes that staying informed about product recalls is essential for consumer safety. Recalls can be initiated voluntarily by a manufacturer or at the request of the FDA. The agency notes that while many recalls result in products being pulled from the market, some issues can be corrected without removing products from distribution. Between 2014 and 2024, more than 83,000 FDA-regulated products were recalled in the U.S. For now, consumers in possession of the affected deodorants are advised to stop using them and refer to the FDA's recall database for next steps.
Arab Times
2 days ago
- Arab Times
New study links COVID-19 vaccine to potential eye damage
NEW YORK, July 19: A new scientific study has found that Pfizer's COVID-19 vaccine may cause temporary changes in the eyes' corneal structure, raising concerns about long-term vision health, particularly for individuals with pre-existing eye conditions. Researchers in Turkey studied 64 participants who received both doses of the Pfizer-BioNTech vaccine and discovered measurable changes to the cornea's innermost layer, known as the endothelium. This thin cell layer is vital for keeping the cornea clear by pumping out excess fluid. The study was published Wednesday in the journal Ophthalmic Epidemiology. The scientists observed that, within two months of vaccination, participants showed a slight thickening of the cornea, a decrease in endothelial cell count, and greater variability in the size of these cells — all potential signs of short-term stress on the eye. 'These changes suggest the vaccine may temporarily weaken the endothelium, though none of the participants experienced vision problems during the study,' the researchers noted. The average corneal thickness increased from 528 to 542 micrometers — about a 2% change. Meanwhile, endothelial cell density dropped from an average of 2,597 to 2,378 cells per square millimeter — an 8% decrease. While this remains within normal limits for healthy adults, the decline could pose a risk for people with already low cell counts, such as those with prior eye surgeries, infections, or conditions like Fuchs' dystrophy. The study also found a drop in the proportion of endothelial cells with a healthy hexagonal shape, from 50% to 48%, and an increase in the coefficient of variation in cell size from 39 to 42 — further indicators of stress or damage. 'These changes are subtle and may not cause immediate harm, but they warrant monitoring, especially in individuals with compromised corneal health,' the authors stated. The research team did not recommend against COVID-19 vaccination but emphasized the need for further long-term studies to determine whether the observed changes persist or worsen over time. 'If these effects on the endothelium continue for years, they could contribute to eye diseases such as corneal edema, bullous keratopathy, or corneal decompensation — all of which can lead to permanent vision loss if left untreated,' the study warned. Specialists recommend that people with eye discomfort or blurry vision consult an ophthalmologist. A non-invasive test using a specular microscope can determine endothelial cell health. The study adds to a growing list of side-effect concerns linked to COVID-19 vaccines. In May, the U.S. Food and Drug Administration (FDA) expanded its warning labels on Pfizer and Moderna vaccines to include risks of myocarditis and pericarditis — types of heart inflammation — particularly in males aged 16 to 25. Despite these concerns, health authorities maintain that the benefits of COVID-19 vaccination continue to outweigh the risks for the majority of the population. The Turkish study involved 128 eyes (64 participants), with each subject undergoing full ophthalmic examinations before receiving their first vaccine dose and approximately 75 days after their second. Researchers used high-precision tools — including Sirius corneal topography and the Tomey EM-4000 specular microscope — to assess corneal thickness and endothelial cell characteristics.
Arab Times
05-05-2025
- Arab Times
New AI tool shows promise in treating depression, anxiety, and eating disorders
NEW YORK, May 5: Researchers at a leading academic institution have developed an artificial intelligence-powered chatbot aimed at addressing the growing gap in access to mental health services. The tool, known as Therabot, is positioned as a credible alternative to the unregulated wave of mental health apps currently saturating the digital marketplace. According to the team behind the project, even a dramatic increase in the number of human therapists would not be sufficient to meet the growing demand for mental health care. Their solution: a digital platform that can provide reliable, science-based support to individuals dealing with conditions such as anxiety, depression, and eating disorders. A recently published clinical study highlighted Therabot's effectiveness in reducing symptoms across those disorders. A follow-up trial is planned to compare the chatbot's performance directly against traditional therapy methods. The medical and psychological communities appear cautiously optimistic about the use of AI in this space. One healthcare innovation leader from a major psychological association described the potential of AI-driven mental health support as 'promising,' provided it is developed ethically and responsibly. However, concerns remain, especially regarding how younger users may interact with such tools. The development team behind Therabot has invested nearly six years into building the chatbot, emphasizing user safety and therapeutic value over commercial gain. Rather than relying solely on real-world therapy transcripts, the developers constructed detailed simulated conversations to train the AI, enhancing its understanding of patient-caregiver dynamics. The team is also considering launching a nonprofit branch to help ensure access for individuals who cannot afford traditional therapy. In contrast to many commercially driven apps, which critics say often prioritize engagement over well-being, the Therabot developers aim to build genuine therapeutic connections and trust with users. Experts warn that many apps in the market feed users what they want to hear, which may mislead or emotionally manipulate, especially younger audiences. While the U.S. Food and Drug Administration does not formally certify AI-based mental health apps, it may authorize them for marketing after reviewing pre-market submissions. The agency has acknowledged the potential for digital tools to improve access to behavioral therapy. Other developers in the space are also working on AI-powered therapy solutions. One competing app claims to be able to detect signs of crisis or suicidal ideation and send alerts to prevent harm. The creators of this app argue that their design avoids the risks associated with less rigorously developed chatbots. Despite their potential, experts agree that AI therapy tools are currently better suited for day-to-day emotional support rather than severe psychiatric crises. However, their constant availability makes them a valuable resource for individuals seeking support at unconventional hours—something not always possible with human therapists. Some individuals have already turned to general AI platforms for mental health support, with one user reporting significant personal benefit in managing trauma-related stress. While such tools are not officially designed for therapy, their accessibility and responsiveness offer comfort to those in distress. As AI continues to shape the future of mental health care, developers and medical professionals alike stress the importance of balancing innovation with ethical responsibility and robust oversight.
